Patients with heart failure (HF) with reduced left ventricle ejection fraction (HFrEF) are at high risk of sudden cardiac death (SCD). Therefore HFrEF treatment requires further improvement, which may be accomplished with the use of sacubitril/valsartan. Sacubitril/valsartan reduce the risks of allcause mortality, cardiovascular mortality, SCD, HF mortality, HF and all-cause hospitalizations, as well as symptoms of HF. It was also shown that use of sacubitril/valsartan may be associated with a reduced number of adequate and inadequate device interventions in HFrEF patients with an implantable cardioverter defibrillator, and an increased percentage of biventricular pacing in patients with cardiac resynchronization therapy. Sacubitril/valsartan blocks the angiotensin II receptor (valsartan) and inhibits neprilysin (sacubitril) simultaneously. It results in inhibited sympathetic activity, as well as decreased cardiac remodeling and fibrosis, resulting in a decreased pro-arrhythmogenic effect.
Current trends show that the prevalence of heart failure (HF) is still increasing (1) . Patients with HF with reduced left ventricle ejection fraction (HFrEF) are at high risk of sudden cardiac death (SCD) (2) . In the PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial approximately 40% of deaths of HFrEF patients were related to SCD caused mainly by ventricular arrhythmia (3) . The risk of SCD in HFrEF may be reduced with guideline-recommended treatment with angiotensin converting enzyme inhibitors (ACE-I), beta-blockers, mineralocorticoid receptor antagonists (MRA), as well as with device therapies such as implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT). Angiotensin-receptor blockers (ARB) should be restricted to patients unable to tolerate ACE-I or potentially used in addition to ACE-I instead of MRA in the case of intolerance (2) . The PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With an Angiotensin-Con-verting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) study was terminated ahead of time (after a median of 27 months of observation) because of observed clear benefits of sacubitril/valsartan compared to enalapril. Sacubitril/valsartan significantly reduced the risks of all-cause mortality, cardiovascular mortality, SCD, HF mortality, HF and all-cause hospitalizations, as well as symptoms of HF (3) . It is important that the advantages of treatment with sacubitril/valsartan persist even after the need for dose reduction and are similar to those observed in patients without any dose reduction (4) . It was also shown that use of sacubitril/valsartan was also associated with a reduced number of adequate and inadequate device interventions in HFrEF patients with an implanted ICD. Sacubitril/valsartan reduced the risk of sustained and nonsustained ventricular tachycardia, as well as the risk of premature ventricular contractions, which translated into a higher rate of biventricular pacing in patients with CRT. In addition, a trend was observed to reduce the incidence of paroxysmal atrial tachycardia and atrial fibrillation (5) . In the PARADIGM-HF study patients treated with sacubitril/valsartan were less likely to require implantation of a cardiac device or cardiac transplantation (3) . Sacubitril/valsartan blocks the angiotensin II receptor (valsartan) and inhibits neprilysin (sacubitril) simultaneously. Inhibition of the AT2 receptor results in decreased sympathetic activity and inhibits cardiac hypertrophy, reverse remodeling and fibrosis, and therefore inhibits the pro-arrhythmogenic effect. Neprilysin is an enzyme that degrades natriuretic and vasoactive peptides and is overstimulated in patients with HF. Neprilysin inhibition, by sacubitril, causes beneficial effects on the cardiovascular system through the vasodilating effect and increasing the availability of natriuretic peptides, which in turn leads to growth of natriuresis and diuresis, as well as reduction of left ventricular and vascular remodeling (6, 7) . The reduction of the risk of ventricular arrhythmia in the PARADIGM trial might have resulted from intensification of HF treatment through connection of these two moleculessacubitril and valsartan. Reduction of preload and afterload, improvement of the left ventricular function obtained by neprilysin inhibition, as well as reduction of myocardial fibrosis, myocardial ischemia and sympathetic tone by valsartan, might play an important role in modification of the substrate for fatal ventricular arrhythmias.
Mortality benefits of sacubitril/valsartan use are particularly related to modification of the risk for SCD and death due to HF worsening, giving a real chance for further improvement in HF therapy.
